Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial

Avecho Biotechnology (ASX:AVE) has dosed the first patient in the Phase III clinical trial of its anti-insomnia medication, according to a Thursday filing with the Australian bourse. The trial targets

MT NewswiresMay 15 21:42 ET

Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial

Avecho Biotechnology (ASX:AVE) has begun patient recruitment for the Phase III clinical trial of its anti-insomnia medication, the company said in a Tuesday filing with the Australian Securities Excha

MT NewswiresMar 25 18:37 ET

Avecho to Push Forward With Phase III Trial of Anti-Insomnia Drug

Avecho Biotechnology (ASX:AVE) said the Australian Therapeutic Goods Administration (TGA) has "not recommended any changes" to the design and submission strategy of the firm's proposed Phase III clini

MT NewswiresMar 14 07:41 ET

Avecho Biotechnology Secures Ethics Clearance for Phase Three Insomnia Trial

Avecho Biotechnology (ASX:AVE) secured ethics approval to advance its phase three insomnia trial, according to a filing with the Australian Securities Exchange on Thursday. The study aims to investiga

MT NewswiresMar 7 01:11 ET

Stocks of the Hour: Dotz Nano, Immuron, Avecho Biotechnology

To register for Friday's webinar click here.Dotz Nano (ASX:DTZ, OTC:DTZNY), a leading developer of innovative climate and industrial nanotechnologies, today announced the completion of a bench-scale d

sharecafeMar 6 19:43 ET

Avecho Biotechnology (ASX:AVE) Passes "Crucial" Two-year Stability Milestone for CBD Capsule

The Market HeraldJun 22, 2023 01:33 ET